Drug resistance and possible therapeutic options against influenza A virus infection over past years
- PMID:39499323
- DOI: 10.1007/s00203-024-04181-3
Drug resistance and possible therapeutic options against influenza A virus infection over past years
Abstract
Influenza A virus infection, commonly known as the flu, has persisted in the community for centuries. Although we have yearly vaccinations to prevent seasonal flu, there remains a dire need for antiviral drugs to treat active infections. The constantly evolving genome of the influenza A virus limits the number of effective antiviral therapeutic options. Over time, antiviral drugs become inefficient due to the development of resistance, as seen with adamantanes, which are now largely ineffective against most circulating strains of the virus. Neuraminidase inhibitors have long been the drug of choice, but due to selection pressure, strains are becoming resistant to this class of drugs. Baloxavir marboxil, a drug with a novel mode of action, can be used against strains resistant to other classes of drugs but is still not available in many countries. Deep research into nanoparticles has shown they are effective as antiviral drugs, opening a new avenue of research to use them as antiviral agents with novel modes of action. As this deadly virus, which has killed millions of people in the past, continues to develop resistance, there is an urgent need for new therapeutic agents with novel modes of action to halt active infections in patients. This review article covers the available therapeutic antiviral drug options with different modes of action, their effectiveness, and resistance to various strains of influenza A virus.
Keywords: Baloxavir marboxil; Influenza A virus; M2 ion channel inhibitors; Nanoparticles; Neuraminidase inhibitors.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
- Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, Srivastava T, Hill H, Ku CC, Ren S, Rothery C, Bojke L, Sculpher M, Woods B.Harnan S, et al.Health Technol Assess. 2024 Oct;28(73):1-230. doi: 10.3310/YAPL9347.Health Technol Assess. 2024.PMID:39487661Free PMC article.
- Trends in Surgical and Nonsurgical Aesthetic Procedures: A 14-Year Analysis of the International Society of Aesthetic Plastic Surgery-ISAPS.Triana L, Palacios Huatuco RM, Campilgio G, Liscano E.Triana L, et al.Aesthetic Plast Surg. 2024 Oct;48(20):4217-4227. doi: 10.1007/s00266-024-04260-2. Epub 2024 Aug 5.Aesthetic Plast Surg. 2024.PMID:39103642Review.
- Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.Ryan R, Hill S.Ryan R, et al.Cochrane Database Syst Rev. 2019 Oct 23;10(10):ED000141. doi: 10.1002/14651858.ED000141.Cochrane Database Syst Rev. 2019.PMID:31643081Free PMC article.
- Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.Shabaninejad H, Kenny RP, Robinson T, Stoniute A, O'Keefe H, Still M, Thornton C, Pearson F, Beyer F, Meader N.Shabaninejad H, et al.Health Technol Assess. 2024 Oct;28(75):1-75. doi: 10.3310/TGAC4201.Health Technol Assess. 2024.PMID:39487741Free PMC article.
- Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managingTrichophyton indotineae infections.Gupta AK, Wang T, Mann A, Polla Ravi S, Talukder M, Lincoln SA, Foreman HC, Kaplan B, Galili E, Piguet V, Shemer A, Bakotic WL.Gupta AK, et al.Expert Rev Anti Infect Ther. 2024 Sep;22(9):739-751. doi: 10.1080/14787210.2024.2390629. Epub 2024 Aug 18.Expert Rev Anti Infect Ther. 2024.PMID:39114868Review.
References
- Abed Y, Boivin G (2017) A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir. In: Open forum infectious diseases. Oxford University Press US
- Araste F, Bakker AD, Zandieh-Doulabi B (2023) Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. J Nanopart Res 25(11):229 - DOI
- Ashraf MA et al (2024) A comprehensive review of influenza B virus, its biological and clinical aspects. Front Microbiol 15.https://doi.org/10.3389/fmicb.2024.1467029
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous